List of Excipients in Branded Drug mounjaro

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Eli Lilly and Company	MOUNJARO	tirzepatide	0002-1506	HYDROCHLORIC ACID	2028-12-19
Eli Lilly and Company	MOUNJARO	tirzepatide	0002-1506	SODIUM CHLORIDE	2028-12-19
Eli Lilly and Company	MOUNJARO	tirzepatide	0002-1506	SODIUM HYDROXIDE	2028-12-19
Eli Lilly and Company	MOUNJARO	tirzepatide	0002-1506	SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE	2028-12-19
Eli Lilly and Company	MOUNJARO	tirzepatide	0002-1506	WATER	2028-12-19

Mounjaro Excipient Strategy and Commercial Opportunities for Tirzepatide

Last updated: August 9, 2026

Mounjaro contains a relatively simple injectable formulation: tirzepatide, sodium chloride, sodium phosphate dibasic heptahydrate, and water for injection, with hydrochloric acid or sodium hydroxide used for pH adjustment. The commercial opportunity is therefore concentrated less in novel excipient discovery and more in high-volume supply, sterile injectable manufacturing, cartridge and pen compatibility, stability assurance, and alternative presentation development.[1]

Eli Lilly's core competitive protection is centered on tirzepatide composition, peptide-conjugate chemistry, manufacturing, formulation, device, and method-of-use patents. Excipient suppliers can participate without challenging the active-ingredient estate, but they must meet Lilly's high requirements for injectable quality, extractables and leachables, supply continuity, and regulatory documentation.

What excipients are used in Mounjaro?

Mounjaro's commercial formulation uses a short excipient list.

Component	Function	Commercial relevance
Tirzepatide	Active pharmaceutical ingredient	Synthetic peptide and primary intellectual-property barrier
Sodium chloride	Tonicity adjustment	Commodity excipient with injectable-grade supply requirements
Sodium phosphate dibasic heptahydrate	Buffering and pH control	Injectable buffer with potential sourcing and consistency requirements
Water for injection	Vehicle	Sterile manufacturing and validated water-system requirement
Hydrochloric acid and sodium hydroxide	pH adjustment	Process-control materials rather than principal formulation excipients

The FDA label identifies Mounjaro as a clear, colorless to slightly yellow solution for subcutaneous administration. The product is supplied in single-dose pens and single-dose vials at multiple strengths.[1]

The formulation's simplicity reduces the immediate opportunity for differentiated excipient chemistry. It increases the importance of execution: low endotoxin levels, low bioburden, tight osmolality control, validated compatibility with primary containers, and reliable global supply.

Why is Mounjaro's excipient strategy commercially important?

The formulation must preserve tirzepatide potency and quality during manufacturing, storage, transport, and repeated commercial scale-up. A simple formulation can still create substantial technical barriers because peptides are sensitive to aggregation, adsorption, oxidation, deamidation, and interface effects.

The principal commercial requirements are:

1. Consistent buffer and tonicity control across all strengths.
2. Compatibility with glass, elastomer closures, cartridges, and pen assemblies.
3. Low particulate and endotoxin burden.
4. Stable performance across cold-chain excursions.
5. Scalable sterile filtration and aseptic filling.
6. Documentation that supports Lilly's global regulatory filings.

For suppliers, the opportunity is strongest when the excipient is bundled with technical services, analytical support, and validated supply rather than sold as a commodity alone.

What formulation patents protect Mounjaro?

Mounjaro's relevant patent estate is broader than its excipient list. Public patent records identify Lilly-owned or Lilly-originating rights covering tirzepatide and related peptide-conjugate technology, including U.S. Patent No. 10,034,938, which is associated with peptide-conjugate inventions and has a later expiration horizon than the product's initial regulatory exclusivity.[2]

The commercial protection can be divided into four categories:

Tirzepatide composition patents

These cover the active peptide, peptide analogs, conjugates, and related molecular structures. They are the most significant barrier to an unauthorized copy of tirzepatide.

Manufacturing patents

These can cover peptide synthesis, purification, conjugation, crystallization, impurity control, and processes used to produce commercial-grade tirzepatide. A competitor may need to design around these rights even after obtaining a product approval.

Formulation patents

Formulation claims can cover concentration, pH, buffer systems, stabilizers, containers, or combinations of tirzepatide with specific excipients. The commercial formulation's short excipient list does not eliminate the possibility of formulation-based patent protection.

Method-of-use patents

Lilly has extensive commercial interest in tirzepatide use for type 2 diabetes, obesity, weight management, cardiovascular risk, sleep apnea, and other metabolic indications. The scope and enforceability of method claims will depend on the approved indication, label language, prescribing behavior, and applicable jurisdiction.

Patent expiration dates must be assessed family by family. Patent term adjustment, patent-term extension, terminal disclaimers, continuations, and later-filed formulation or use patents can produce different end dates. A single "Mounjaro patent expiration date" is therefore not a reliable commercial metric.

What is the Orange Book status of Mounjaro?

Mounjaro was approved by the FDA under NDA 215866, not under a biologics license application.[1] The product is therefore evaluated through the Hatch-Waxman framework rather than the Purple Book biosimilar framework.

The Orange Book is relevant because it can identify patents submitted for the approved drug and provide the basis for Paragraph IV certifications by ANDA applicants. The practical questions are:

• Which Lilly patents are listed against NDA 215866?
• Which listed patents have the latest expiration dates?
• Are the claims directed to active ingredient, formulation, method of use, or drug delivery?
• Has any ANDA applicant issued a Paragraph IV notice?
• Has Lilly filed an infringement action within the statutory period?

The FDA Orange Book should be treated as the controlling source for listed patents and exclusivity status. Patent databases and commercial reports are useful for family mapping, but they should not replace the current Orange Book record.[3]

When does Mounjaro lose exclusivity?

Mounjaro's market protection has two separate components: FDA regulatory exclusivity and patent exclusivity.

Protection type	Commercial effect
New chemical entity exclusivity	Blocks certain ANDA approvals for the statutory period
Listed patents	Can delay approval or launch of an ANDA
Patent-term adjustment	Can extend the effective patent term beyond the nominal 20-year period
Patent-term extension	May extend one qualifying patent for a portion of regulatory review time
Method-of-use patents	May permit approval with a carved-out label, depending on claim scope
Formulation and device patents	May create later barriers even after composition protection weakens

Mounjaro was approved in May 2022. FDA approval triggered a five-year new chemical entity exclusivity period for the active ingredient, subject to the applicable statutory framework.[1] That regulatory period does not determine the final generic launch date. Listed patents and litigation may extend practical market protection.

The commercial risk is likely to rise in stages:

1. Early patent intelligence and formulation development.
2. ANDA preparation and Paragraph IV filing activity.
3. Patent litigation and possible settlement.
4. First tentative approvals.
5. At-risk launches after litigation stays expire or are resolved.
6. Broader competition after the strongest composition and manufacturing claims expire.

Which companies are challenging Mounjaro's patent estate?

Publicly visible competitive activity around tirzepatide has included generic, biosimilar-like, compounding, and alternative GLP-1/GIP development programs. These categories should not be treated as equivalent.

An ANDA applicant would need to address Mounjaro's listed patents through Paragraph I, II, III, or IV certifications. A Paragraph IV certification asserts that a listed patent is invalid, unenforceable, or not infringed. Lilly could then bring an infringement action, potentially triggering a 30-month stay of FDA approval under Hatch-Waxman.[4]

As of the cited public FDA and Lilly materials, there is no basis to describe a settled, final generic launch date for Mounjaro. A market participant should distinguish between:

• Companies developing tirzepatide products;
• Compounding pharmacies;
• API or peptide manufacturers;
• ANDA applicants;
• Companies developing competing GLP-1 or GIP medicines.

Each presents a different legal and commercial risk.

Is Mounjaro exposed to biosimilar competition?

Mounjaro is not a biosimilar product because Lilly received an NDA approval rather than a BLA approval. The formal abbreviated pathway for biosimilars under the Public Health Service Act does not apply to Mounjaro.[5]

The relevant follow-on risk is an ANDA or, in some circumstances, a 505(b)(2) application. Tirzepatide's peptide structure and injectable presentation may allow a follow-on applicant to pursue an abbreviated pathway, but the applicant would still face:

• Reference-product patent litigation;
• Demonstration of pharmaceutical equivalence;
• Device or presentation requirements;
• Peptide impurity and aggregation controls;
• Injectable manufacturing validation;
• Labeling limitations for patented indications;
• Potential manufacturing-process patent claims.

The absence of a biosimilar pathway does not remove competition. It changes the regulatory and litigation route.

What excipient opportunities exist for Mounjaro suppliers?

The most credible opportunities are platform and supply-chain opportunities.

Injectable-grade sodium chloride and phosphate

Large-scale tirzepatide production requires reliable pharmaceutical-grade buffer and tonicity materials. Suppliers can compete through validated low-endotoxin grades, global inventory, dual manufacturing sites, and documentation packages that shorten regulatory review.

Sterile water and process systems

Water for injection is a core manufacturing input. Opportunity exists in high-purity water systems, microbial-control services, continuous monitoring, and aseptic processing support.

Container-closure compatibility

Mounjaro's pen and vial presentations create demand for compatible glass, elastomers, lubricants, adhesives, and polymer components. Suppliers that can provide extractables and leachables data, particulate testing, and peptide adsorption studies have stronger positioning than commodity vendors.

Peptide stabilization platforms

A future Lilly presentation could use a different buffer, surfactant, sugar, amino acid, or lyophilization system to support longer shelf life, less refrigeration, higher concentration, or a new delivery device. Such changes would face technical and regulatory hurdles but could create licensing opportunities for excipient companies with validated peptide-stabilization technology.

Device-linked formulation systems

The most valuable commercial opportunity may involve the interaction between formulation and device. Higher-concentration tirzepatide products, multidose systems, autoinjectors, and alternative delivery platforms require coordinated development of viscosity, injection force, container compatibility, and dose accuracy.

What manufacturing and IP barriers affect excipient commercialization?

An excipient supplier does not automatically avoid Lilly's patent estate. A supplier may face contractual, confidentiality, process, or inducement risks if it knowingly supports an infringing product.

Key barriers include:

• Lilly-specific specifications that are not disclosed in the public label;
• Supplier qualification and audit requirements;
• Long-term quality agreements;
• Restricted changes to manufacturing sites or raw-material sources;
• Container and device compatibility data;
• Patent claims covering formulation combinations;
• Process patents involving excipient addition or purification;
• Regulatory change-control obligations.

For follow-on manufacturers, the lowest-risk approach is usually to use well-established injectable excipients in concentrations supported by prior art and to avoid unnecessary formulation innovation. That strategy may reduce formulation-patent exposure but does not address tirzepatide composition or manufacturing patents.

How does Mounjaro compare with competing incretin products?

Product	Active ingredient	Approval route	Primary follow-on risk	Excipient opportunity
Mounjaro	Tirzepatide	NDA	ANDA, Paragraph IV, formulation and process patents	Injectable supply, pens, peptide stabilization
Ozempic	Semaglutide	NDA	ANDA and patent litigation	Pen systems, peptide-compatible materials
Wegovy	Semaglutide	NDA	ANDA and patent litigation	Higher-volume obesity formulations
Trulicity	Dulaglutide	BLA	Biosimilar pathway and device complexity	Biologic formulation and device supply
Victoza	Liraglutide	NDA	Generic and patent expiry exposure	Injectable formulation and pen components

Mounjaro has a stronger commercial growth profile than many earlier incretin products, but its excipient formulation is less differentiated on its face. The value lies in scale, quality, device integration, and future lifecycle products.

What revenue exposure does Mounjaro create?

Mounjaro generated approximately $11.5 billion in 2024 revenue for Eli Lilly, according to the company's annual report.[6] That scale supports substantial demand for:

• Tirzepatide API and peptide-conjugation inputs;
• Injectable excipients;
• Sterile fill-finish capacity;
• Pen and vial components;
• Cold-chain logistics;
• Analytical and quality-control services.

Revenue exposure is concentrated in Lilly's manufacturing network and approved-market expansion. A supplier's opportunity is strongest when it has multi-year capacity commitments and can support multiple geographic markets. A single-site supplier carries substantial interruption risk because a supply failure can affect a high-revenue product with global demand.

What is the litigation and settlement outlook for Mounjaro?

Mounjaro's principal litigation risk is likely to involve patent validity, infringement, and regulatory timing rather than excipient-only disputes. Paragraph IV activity could trigger district-court litigation, a 30-month stay, settlement negotiations, or a license with a delayed generic entry date.[4]

A settlement could define:

• The earliest authorized generic entry date;
• Whether the entrant can launch with a carved-out label;
• Whether the agreement includes a supply or license component;
• Restrictions on API sourcing;
• Treatment of later-issued continuation patents;
• Potential acceleration if a patent is invalidated.

No commercial forecast should assume that the first patent expiration equals the first generic launch. Settlement terms, litigation outcomes, patent listing practice, and the availability of non-infringing manufacturing routes can materially change the timing.

Key Takeaways

• Mounjaro's public formulation uses tirzepatide, sodium chloride, sodium phosphate dibasic heptahydrate, water for injection, and pH adjusters.
• The formulation is chemically simple but operationally demanding because it is a sterile injectable peptide product.
• The strongest excipient opportunities are in validated supply, container-closure systems, peptide stabilization, sterile manufacturing, and device integration.
• Mounjaro is an NDA product, so ANDA and Paragraph IV analysis is more relevant than biosimilar analysis.
• Lilly's patent protection extends beyond the active molecule to manufacturing, formulation, delivery systems, and methods of use.
• Mounjaro generated about $11.5 billion in 2024 revenue, creating a large addressable market for qualified excipient and injectable-component suppliers.
• A generic launch date cannot be inferred from one patent expiration. Orange Book listings, patent families, litigation, settlements, and manufacturing design-arounds must be assessed together.

FAQs

Can a new excipient be used to create a differentiated Mounjaro follow-on product?

Yes, but a new excipient may trigger additional formulation development, stability studies, device testing, and regulatory review. It does not eliminate Lilly's composition or process patents.

Does Mounjaro's simple excipient list mean it has weak formulation protection?

No. A short ingredient list can still support claims directed to concentration, pH, stability, container compatibility, manufacturing conditions, or specific excipient combinations.

Can a supplier sell Mounjaro-compatible excipients to generic manufacturers?

Generally, an excipient supplier can sell standard pharmaceutical materials, but the buyer's use may implicate product, process, formulation, or inducement theories. Contractual restrictions and customer qualification terms also matter.

Are compounded tirzepatide products a durable commercial threat to Mounjaro?

Compounding activity depends heavily on FDA shortage determinations and applicable federal and state law. It is not equivalent to an FDA-approved generic and does not provide the same regulatory substitution pathway.

Which Mounjaro presentation offers the largest excipient opportunity?

Higher-volume pen systems and future concentrated or multidose presentations offer the greatest potential because they create demand for formulation-device compatibility, injection-force control, container materials, and improved peptide stability.

References

1. U.S. Food and Drug Administration. (2025). Mounjaro (tirzepatide) prescribing information.
2. United States Patent and Trademark Office. (n.d.). U.S. Patent No. 10,034,938, peptide conjugates.
3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book.
4. U.S. Code, 21 U.S.C. § 355(j).
5. U.S. Food and Drug Administration. (2015). Biosimilars: Questions and answers regarding implementation of the Biologics Price Competition and Innovation Act of 2009.
6. Eli Lilly and Company. (2025). 2024 annual report.